Delta14-sterol reductase activity GO:0050613

Delta14-sterol reductase activity (GO:0050613) is a molecular function that catalyzes the NADPH-dependent reduction of the C14-C15 double bond in sterol intermediates, a critical step in the cholesterol biosynthesis pathway. This enzymatic activity converts 4,4-dimethyl-5-alpha-cholesta-8,24-dien-3-beta-ol to 4,4-dimethyl-5-alpha-cholesta-8,14,24-trien-3-beta-ol, while oxidizing NADPH to NADP+. The reaction is part of the post-squalene segment of sterol biosynthesis, which is essential for the production of cholesterol and other sterols in eukaryotic cells. Researchers study Delta14-sterol reductase activity because of its central role in membrane biogenesis and its emerging connection to human disease, particularly demyelinating conditions such as multiple sclerosis. The enzyme is thought to be localized to the endoplasmic reticulum membrane, where it participates in a multi-step enzymatic cascade. Understanding its mechanism, regulation, and genetic control is vital for developing therapeutic strategies targeting sterol metabolism. This article provides a comprehensive overview of GO:0050613, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods including CRISPR-based models.

Delta14-sterol reductase activity (GO:0050613) is defined as the catalysis of the reaction: NADP+ + 4,4-dimethyl-5-alpha-cholesta-8,24-dien-3-beta-ol = NADPH + H+ + 4,4-dimethyl-5-alpha-cholesta-8,14,24-trien-3-beta-ol. In simpler terms, it is an oxidoreductase that removes a double bond at the C14 position of a sterol precursor using NADPH as an electron donor. This activity is synonymous with C-14 sterol reductase, sterol C14-reductase, and D14-sterol reductase.

Delta14-sterol reductase activity is crucial for the biosynthesis of cholesterol, a fundamental component of cell membranes and a precursor for steroid hormones, bile acids, and vitamin D. Impairments in this enzymatic step can lead to the accumulation of toxic sterol intermediates, which have been associated with demyelination and neurodegeneration, as observed in multiple sclerosis models. Therefore, understanding this activity is essential for elucidating the molecular basis of sterol-related disorders and for identifying potential therapeutic targets.

The following genes and proteins are associated with Delta14-sterol reductase activity and related sterol biosynthesis pathways.

Delta14-sterol reductase activity is regulated at multiple levels, including transcriptional control by sterol regulatory element-binding proteins (SREBPs) and feedback inhibition by cholesterol and oxysterols. Post-translational modifications and membrane lipid composition may also influence enzyme activity. Additionally, the redox state of the cell, particularly the NADPH/NADP+ ratio, can modulate the enzyme's catalytic efficiency.

Alterations in sterol biosynthesis, including Delta14-sterol reductase activity, have been observed in demyelination models of multiple sclerosis. Accumulation of sterol intermediates may contribute to oligodendrocyte dysfunction and myelin damage.

Mutations in genes encoding Delta14-sterol reductase activity, such as LBR, cause Greenberg dysplasia and Pelger-Huet anomaly, characterized by skeletal abnormalities and nuclear lobulation defects.

Dysregulated cholesterol synthesis is a hallmark of many cancers, and targeting enzymes like Delta14-sterol reductase may offer therapeutic opportunities.

In vitro assays using radiolabeled or fluorescent sterol substrates and NADPH can directly measure Delta14-sterol reductase activity. These assays are used to determine kinetic parameters and inhibitor efficacy.

LC-MS/MS-based lipidomics can quantify sterol intermediates and end products, providing a snapshot of pathway flux and enzyme activity in cells or tissues.

Knockout, point mutation, and knock-in models generated via CRISPR-Cas9 allow researchers to study the consequences of altered Delta14-sterol reductase activity in a physiological context.

RNA-seq and proteomics can reveal changes in gene expression and protein abundance in response to modulation of Delta14-sterol reductase activity.

Researchers studying Delta14-sterol reductase activity-related genes often need to determine whether a candidate gene is causally involved in sterol metabolism, membrane integrity, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.

Delta14-sterol reductase activity (GO:0050613) is a critical enzymatic step in cholesterol biosynthesis with significant implications for human health and disease. Understanding its mechanism, regulation, and genetic control is essential for developing targeted therapies for demyelinating disorders, developmental defects, and cancer. Advanced CRISPR-based models and multi-omics approaches will continue to illuminate its roles in physiology and pathology.